TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00353223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal and behavioral psychotherapy
Description: Participants will receive a combined intervention of interpersonal and behavioral psychotherapy designed for people with heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours. The psychotherapy sessions will allow participants to discuss how they are coping with their illness and loss of functioning. They will also aim to help participants with heart failure to develop new recreational activities in keeping with their new level of functioning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control (AC) condition
Description: The AC group will not receive therapy. Instead, a clinician will ask them questions about their depression and heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours.
Study: NCT02267915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous Rituximab
Description: MabThera 1400 mg solution for subcutaneous injection
Study: NCT02405767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot ulcer impedance
Description: lmpedence measured using ECG electrodes placed at the periphery of the wound (when the wound dressing is changed as part of standard care).
Study: NCT00791219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBA-itraconazole
Description: 100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA™-Itraconazole 50 mg capsules (HalcyGen Ltd)
Study: NCT03538938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives for Treatment Engagement
Description: Incentives for treatment engagement are for each counseling session and for staying enrolled in SmokefreeTXT for six weeks. These incentives are designed to bolster motivation to stay engaged in treatment and to offset the costs and effort of treatment engagement (in terms of cell phone minutes).
Study: NCT00791219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: 200 mg taken with breakfast of SPORANOX® (itraconazole) 100 mg capsules (Janssen Pharma).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules taken approximately 30 minutes prior to breakfast
Study: NCT00441285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel
Description: - Praziquantel 50 mg / kg / d (up to 3600 mg / d ) for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: * Albendazole 15 mg / kg / d ( up to 800 mg /d ) in Arm I for 10 days.~* Albendazole at an increased dose, 22.5 mg / kg / d (up to 1200 mg / d ), in Arm II for 10 days.
Study: NCT03538938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives for Treatment Engagement
Description: Incentives for treatment engagement are for each counseling session and for staying enrolled in SmokefreeTXT for six weeks. These incentives are designed to bolster motivation to stay engaged in treatment and to offset the costs and effort of treatment engagement (in terms of cell phone minutes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives for Treatment Engagement
Description: Incentives for treatment engagement are for each counseling session and for staying enrolled in SmokefreeTXT for six weeks. These incentives are designed to bolster motivation to stay engaged in treatment and to offset the costs and effort of treatment engagement (in terms of cell phone minutes).
Study: NCT00441285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: * Albendazole 15 mg / kg / d ( up to 800 mg /d ) in Arm I for 10 days.~* Albendazole at an increased dose, 22.5 mg / kg / d (up to 1200 mg / d ), in Arm II for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: * Albendazole 15 mg / kg / d ( up to 800 mg /d ) in Arm I for 10 days.~* Albendazole at an increased dose, 22.5 mg / kg / d (up to 1200 mg / d ), in Arm II for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABZ Placebo
Description: - Placebo (of Albendazole ) 7.5 mg / kg / d in Arm I and II for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABZ Placebo
Description: - Placebo (of Albendazole ) 7.5 mg / kg / d in Arm I and II for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PZQ Placebo
Description: - Placebo (of Praziquantel) 50 mg / kg / d in Arm II and III for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PZQ Placebo
Description: - Placebo (of Praziquantel) 50 mg / kg / d in Arm II and III for 10 days.
Study: NCT03995888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPSMA-7.3 (18F) Injection
Description: Radioligand for PET CT scanning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPSMA-7.3 (18F) Injection
Description: Radioligand for PET CT scanning
Study: NCT03024983

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Glucose monohydrate (55 g) dissolved with 500 mL of water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semolina soup
Description: Semolina soup (322 g) eaten with 500 mL of water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread
Description: Bread (122 g) eaten with 500 mL of water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Penne (fresh)
Description: Cooked penne (132 g) eaten with 500 mL of water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Penne (dry)
Description: Cooked penne (142 g) eaten with 500 mL of water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spaghetti (dry)
Description: Cooked spaghetti (142 g) eaten with 500 mL of water
Study: NCT03587064

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional 3-lead CRT defibrillator system implantation
Description: Conventional 3-lead(1 atrial and 2 ventricular leads) system implantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-lead CRT defibrillator system implantation
Description: 2-lead (2 ventricular leads with dipole for atrial sensing) DX system implantation
Study: NCT01331369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensification of Care
Description: Usual provided care plus social-psychological intervention: 6 consultation with doctors and 9 with community health workers, both oriented by protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care provided (medical and/or nurse consultation and medicines)
Study: NCT02089048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auranofin
Description: Auranofin is a gold-containing chemical salt available as 3mg capsules. Cohort 1 receives 6mg oral dose of auranofin once every 24 hours for 7 days
Study: NCT03666442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Xelox chemotherapy,that oxaliplatin 130mg/m2 d1,capecitabine 1000mg/m2 twice daily d1-14,every 3 weeks
Study: NCT00039624

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Patients will receive two HDR brachytherapy implants (950-1050 cGy/implant) before and at the end of a course of external beam radiotherapy (4600 cGy, 2Gy/day).
Study: NCT03800316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video Consultation
Description: Video consultation with emergency medicine physicians for patients that are critically ill prior to arrival in the ED
Study: NCT04030598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donidalorsen
Description: Donidalorsen administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donidalorsen
Description: Donidalorsen administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching solution administered SC
Study: NCT02076620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNFα
Description: L19TNFα will be administered as a 2 hours i.v. infusion on days 1, 3, and 5 of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered as a 15 minutes i.v. infusion on day 1 of each 3-week cycle prior L19TNFα administration.
Study: NCT05996939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To compare the efficacy of unstable shoes with that of conventional sports shoes in people with lower-limb primary and secondary lymphedema.
Description: Unstable shoes were compared with conventional sports shoes, the objective being to evaluate possible differences in the evolution of lymphedema. During a clinical trial lasting eight weeks, we assessed quality of life, limb volume, and symptoms derived from lymphedema.
Study: NCT01835912

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Citrate Dihydrate
Description: Dose sodium citrate dihydrate through 2 dosing protocols (Acute and Chronic)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Citrate Dihydrate
Description: Dose sodium citrate dihydrate through 2 dosing protocols (Acute and Chronic)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Citrate Dihydrate
Description: Dose sodium citrate dihydrate through 2 dosing protocols (Acute and Chronic)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Citrate Dihydrate
Description: Dose sodium citrate dihydrate through 2 dosing protocols (Acute and Chronic)
Study: NCT02694133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Smart Phone Based Assistive Speech Therapeutic System
Description: use the mobile device, which with the camera and speaker, for patients to practice the naming training at home, and assess the speech ability every 2-4weeks by speech therapist via telerehabilitation platform. Concise Chinese Aphasia Test (CCAT) will be used as the assessment tool for evaluation speech ability and functional ability.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobile phone-based tele rehabilitation program
Description: Mobile phone-based tele rehabilitation program
Study: NCT03748134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m\^2 IV Q3W day 1
Study: NCT03538938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives for Treatment Engagement
Description: Incentives for treatment engagement are for each counseling session and for staying enrolled in SmokefreeTXT for six weeks. These incentives are designed to bolster motivation to stay engaged in treatment and to offset the costs and effort of treatment engagement (in terms of cell phone minutes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives for Treatment Engagement
Description: Incentives for treatment engagement are for each counseling session and for staying enrolled in SmokefreeTXT for six weeks. These incentives are designed to bolster motivation to stay engaged in treatment and to offset the costs and effort of treatment engagement (in terms of cell phone minutes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives for Treatment Engagement
Description: Incentives for treatment engagement are for each counseling session and for staying enrolled in SmokefreeTXT for six weeks. These incentives are designed to bolster motivation to stay engaged in treatment and to offset the costs and effort of treatment engagement (in terms of cell phone minutes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives for Treatment Engagement
Description: Incentives for treatment engagement are for each counseling session and for staying enrolled in SmokefreeTXT for six weeks. These incentives are designed to bolster motivation to stay engaged in treatment and to offset the costs and effort of treatment engagement (in terms of cell phone minutes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives for Treatment Engagement
Description: Incentives for treatment engagement are for each counseling session and for staying enrolled in SmokefreeTXT for six weeks. These incentives are designed to bolster motivation to stay engaged in treatment and to offset the costs and effort of treatment engagement (in terms of cell phone minutes).
Study: NCT03748134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75mg/m\^2 IV Q3W day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m\^2 IV Q3W day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 87.5 mg/m\^2 IV Q3W day 1, day 8 for first cycle and 175mg/m\^2 IV Q3W day 1 after first cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 87.5 mg/m\^2 IV Q3W day 1, day 8 for first cycle and 175mg/m\^2 IV Q3W day 1 after first cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 87.5 mg/m\^2 IV Q3W day 1, day 8 for first cycle and 175mg/m\^2 IV Q3W day 1 after first cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 800 mg/m\^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: 800 mg/m\^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 800 mg/m\^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
Study: NCT03889249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: Stroke Thrombolytic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Stroke Thrombolytic
Study: NCT04297202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Combined With SHR-1210 Injection
Description: 3 cycles of neoadjuvant therapy before surgery, two weeks is a treatment cycle: D1、D15、D31 : SHR-1210 200mg, I.V, q2w； D1-D20 : Apatinib 250 mg, orally, qd; D46 : Patients were preoperatively evaluated. Operable patients were scheduled for hepatectomy with/without microwave ablation; After 4 to 8 weeks after liver resection, a postoperative adjuvant program is performed. Three weeks is a treatment cycle with a total of 8 cycles~In each cycle:~D1: SHR-1210 200mg, I.V, q3w; D1-D21: Apatinib 250mg, orally, qd;
Study: NCT00689338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: Anidulafungin Intravenous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Oral Administration of Fluconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Oral Administration of Voriconazole
Study: NCT04145856

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: I31 probiotic
Description: I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: I31 probiotic combined to Alverine/Simethicone
Description: * I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)~* Antispasmodic/antifoam drug, consisting of Alverine Citrate 60 mg and Simethicone 300 mg, thrice daily (t.i.d)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment (maltodextrin), once daily (u.i.d)
Study: NCT02464137

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: Patients in each dose cohort will all be treated as a single group. The starting dose will be 8.5 Gy per fraction for 5 fractions (total dose = 42.5 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per fraction.
Study: NCT03669601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: A potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: A potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Nucleoside metabolic inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Nucleoside metabolic inhibitor.
Study: NCT03459625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MSBR)
Description: MBSR includes eight weekly 2.5-hour group sessions, a day-long (6hr) meditation retreat on the weekend during week six, 45 minutes of daily home practice guided by instructional audio CDs, and an MBSR parent workbook. Formal mindfulness exercises aim to increase the capacity for mindfulness and include a body scan, mindful yoga, and sitting meditation. Participants are also taught to practice mindfulness informally in everyday activities. In session, didactic instruction on stress physiology and using mindfulness for coping with stress in daily life is provided. Participants practice formal mindfulness exercises, break into dyads to discuss their daily homework practice, and meet as a larger group to ask questions related to the practice of mindfulness in everyday life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Support Group (PE)
Description: The PE consists of 8-weekly 2.5-hour sessions, a day-long (6hr) Family Resource Fair during week six, daily homework that includes monitoring progress on goals identified at the end of each session, and a workbook for parents of children with special needs that provides parents with information regarding their child's development, disability, and associated considerations. Weekly topics for discussion include Preparing for Individualized Education Plan (IEP) meetings, Communicating with Teachers, Advocacy, Sibling Issues, and Community Resources.
Study: NCT02993198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Study: NCT04253158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational standard
Description: Behavioral intervention aimed at increasing knowledge about alcohol and other drugs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational standard and Harm prevention
Description: Behavioral intervention aimed at increasing knowledge about alcohol and other drugs increasing intentions to use harm prevention strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational standard and Expectancies
Description: Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and shifting alcohol-related expectancies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectancies and Harm prevention
Description: Behavioral intervention aimed at correcting erroneous norms about alcohol use and shifting alcohol-related expectancies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational standard and Normative perceptions
Description: Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and correcting erroneous norms about alcohol use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normative perceptions and Harm prevention
Description: Behavioral intervention aimed at correcting erroneous norms about alcohol use and increasing intentions to harm prevention strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational standard, Normative Perceptions, and Expectancies
Description: Behavioral intervention aimed at increasing knowledge about alcohol and other drugs, correcting erroneous norms about alcohol use, and shifting alcohol-related expectancies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normative perceptions, Expectancies, and Harm Prevention
Description: Behavioral intervention aimed at correcting erroneous norms about alcohol use, shifting alcohol-related expectancies, and increasing intentions to use harm prevention strategies.
Study: NCT02104895

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI)
Description: Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole breast irradiation (WBI)
Description: Conventional whole breast irradiation (WBI)
Study: NCT03538938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Financial Incentives for Treatment Engagement
Description: No Financial Incentives for Treatment Engagement are offered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Financial Incentives for Treatment Engagement
Description: No Financial Incentives for Treatment Engagement are offered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Financial Incentives for Treatment Engagement
Description: No Financial Incentives for Treatment Engagement are offered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Financial Incentives for Treatment Engagement
Description: No Financial Incentives for Treatment Engagement are offered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Financial Incentives for Treatment Engagement
Description: No Financial Incentives for Treatment Engagement are offered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Financial Incentives for Treatment Engagement
Description: No Financial Incentives for Treatment Engagement are offered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Financial Incentives for Treatment Engagement
Description: No Financial Incentives for Treatment Engagement are offered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Financial Incentives for Treatment Engagement
Description: No Financial Incentives for Treatment Engagement are offered.
Study: NCT00655525

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil
Description: 2.9 g of fish oil (2:1 EPA:DHA) administered orally every day for 3 months